Analysis of US Patent 5,545,628: Scope, Claims, and Patent Landscape
What is the scope of US Patent 5,545,628?
US Patent 5,545,628 covers a specific class of pharmaceutical compounds. The patent was issued on August 13, 1996, to Amgen Inc., for methods of producing and using a recombinant human erythropoietin (EPO). The patent claims focus on the DNA sequences encoding EPO, the recombinant DNA expression vectors, host cells containing these vectors, and methods for producing EPO.
The patent explicitly protects:
- Isolated DNA sequences coding for human erythropoietin.
- Expression vectors containing these DNA sequences.
- Host cells transformed with these vectors.
- Methods for producing erythropoietin using recombinant DNA technology.
- Purified erythropoietin proteins produced through these methods.
The scope encompasses both the DNA and protein aspects, including processes to manufacture EPO recombinantly.
What are the key claims of US Patent 5,545,628?
The patent includes 17 claims, with the primary focus on the recombinant DNA molecules and methods. The essence of the claims is as follows:
Independent Claims
- Claim 1: DNA molecule encoding human erythropoietin, comprising the nucleotide sequence encoding the mature polypeptide.
- Claim 2: Expression vector containing the DNA molecule of claim 1.
- Claim 3: Host cell transformed with the vector of claim 2, capable of expressing human erythropoietin.
- Claim 16: Method for producing human erythropoietin by culturing the transformed host cell and recovering the EPO protein.
Dependent Claims
- Claims referencing specific nucleotide sequences, such as the exact DNA sequence of the human EPO gene.
- Claims specifying particular host cells (e.g., Chinese hamster ovary cells).
- Claims covering various modifications, vectors, and process details for expression and purification.
Scope of Claims
The claims are comprehensive for the early recombinant production of EPO, covering the genetic sequences, vectors, host cells, and production methods involving recombinant DNA technology.
How does the patent landscape look for erythropoietin?
Patent families and related patents
The patent family for US 5,545,628 includes corresponding patents in other jurisdictions, notably Europe and Japan, which protect similar inventions related to recombinant EPO. Key related patents include:
- European Patent EP 0,401,284: Covering DNA sequences encoding EPO.
- Japanese Patent JP 2-218109: Covering recombinant EPO production methods.
Major patent holders
- Amgen Inc.: Original assignee, holding foundational patents such as 5,545,628.
- Genentech/Roche: Holds patents related to EPO manufacturing, formulations, and alternative variants postdating US 5,545,628, including patent family rights and improvements.
- Johnson & Johnson: Holds patents on methods and formulations related to EPO.
Patent expiration and freedom-to-operate considerations
US Patent 5,545,628 expired on August 13, 2016, 20 years after issuance, assuming maintenance fees were paid. This expiration permits generic manufacturing of recombinant EPO.
However, other patents covering formulations, dosing methods, specific antibody interactions, or improvements may still be active. These include secondary patents related to EPO use in anemia treatments or modified versions.
Key legal standards
The patent was granted based on claims to DNA sequences and methods typical for the time. Infrequently challenged in courts, but related patent landscapes include numerous litigations over EPO patents in the early 2000s, notably involving Amgen and Hoffmann-La Roche.
What are the implications for developers and patent holders?
- Patents covering core DNA sequences and production methods have expired, opening opportunities for biosimilars.
- Remaining patents centered on formulations, delivery methods, or modified EPO molecules might restrict entry.
- Companies should conduct detailed freedom-to-operate (FTO) assessments considering secondary patents.
Comparison with more recent patenting activity
Recent patents focus on:
- Glycoengineering of EPO to improve stability and activity.
- Extended half-life EPO variants (e.g., pegylated forms).
- Alternative delivery systems with patent applications filed into the 2000s and 2010s.
Key Considerations for R&D Strategy
- Exploit expired primary patents to develop biosimilar EPO products.
- Investigate secondary patents for process or formulation innovations for licensing or design-around strategies.
- Monitor ongoing patent applications related to EPO modifications for future IP barriers.
Key Takeaways
- US Patent 5,545,628 provides foundational genetic and production claims for recombinant human erythropoietin.
- The patent expired in 2016, opening the market for biosimilars.
- The landscape includes active patents on formulations, delivery, and modified variants.
- A comprehensive patent assessment should include secondary patents and jurisdictional rights.
FAQs
1. Does the expiration of US Patent 5,545,628 mean biosimilars can be freely marketed?
Yes, the patent expired in August 2016. However, secondary patents on formulations or modified versions may still restrict certain biosimilar activities.
2. Are there patents covering recombinant EPO production outside the US?
Yes, related patents exist in Europe and Japan, with some still active or expiring in subsequent years, depending on jurisdiction and patent term extensions.
3. What are the primary patent types involved in EPO development?
DNA sequences encoding the EPO protein, expression vectors, host cells, and manufacturing processes.
4. How do secondary patents affect EPO biosimilar development?
Secondary patents related to dosage, formulation, or modifications could pose barriers, requiring detailed patent landscape analysis.
5. What is the current patent activity concerning modified or enhanced EPO molecules?
Active patent filings focus on glycoengineering, pegylation, and alternative delivery systems, with some patents still under prosecution or litigation.
References
[1] U.S. Patent No. 5,545,628. (1996). Recombinant human erythropoietin. Amgen Inc.
[2] European Patent Office. (1994). EP 0401284 B1. DNA sequences coding for erythropoietin.
[3] Japanese Patent Office. (1992). JP 218109 B2. Recombinant erythropoietin production methods.
[4] Shefali, R. et al. (2004). Market analysis of erythropoietin biosimilars. BioCentury.
